The GLP-1 market hit a milestone in 2025 when oral Wegovy received FDA approval — the first oral formulation of semaglutide specifically approved for weight management. For patients who prefer pills over injections, this was a genuine breakthrough. But it also raised an important question: how does the brand-name oral option compare to compounded oral semaglutide alternatives that have been available through telehealth providers?
Here's a clear-eyed comparison of both options as they stand in July 2026.
Oral Wegovy: The Brand-Name Option
What it is: Oral Wegovy (semaglutide) is an FDA-approved tablet formulation manufactured by Novo Nordisk. It uses a novel absorption-enhancement technology to deliver semaglutide through the GI tract — the same active ingredient used in injectable Wegovy, but in pill form.
Approval status: FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related health condition.
How it works: Taken daily on an empty stomach with a small amount of water. Patients must wait at least 30 minutes before eating, drinking, or taking other medications. This fasting requirement is essential for proper absorption.
Pricing: Brand-name oral Wegovy carries a list price comparable to injectable Wegovy — approximately $1,300–$1,400/month. Insurance coverage varies, and manufacturer savings programs may reduce out-of-pocket costs for eligible patients. Without coverage, cash-pay costs remain prohibitive for most patients.
Compounded Oral Semaglutide: The Alternative
What it is: Compounded oral semaglutide is prepared by licensed compounding pharmacies using the same active pharmaceutical ingredient. Available formats include sublingual tablets, sublingual drops, troches (lozenges), and capsules, depending on the pharmacy and provider.
Approval status: Not FDA-approved. Compounded medications are regulated under federal and state pharmacy law and are prepared by licensed pharmacists under physician orders.
How it works: Delivery varies by format. Sublingual formulations dissolve under the tongue for absorption through the oral mucosa, potentially bypassing some of the absorption challenges of GI-tract delivery. Capsule formats follow similar fasting protocols to brand-name oral semaglutide.
Pricing: Compounded oral semaglutide typically ranges from $100 to $350/month through telehealth providers — a significant reduction from brand-name pricing.
Head-to-Head Comparison
| Factor | Oral Wegovy (Brand) | Compounded Oral Sema |
|---|---|---|
| FDA approved | Yes | No |
| Active ingredient | Semaglutide | Semaglutide |
| Monthly cost (cash) | ~$1,300+ | $100–$350 |
| Insurance eligible | Varies by plan | Generally no |
| Format options | Tablet | Tablet, sublingual, troche |
| Fasting required | Yes (30 min) | Varies by format |
| Manufacturer | Novo Nordisk | Licensed compounding pharmacies |
| Quality assurance | FDA manufacturing standards | State pharmacy regulation + testing |
The Price Question
The pricing difference between brand-name and compounded oral semaglutide is the most significant factor for most patients. At roughly 75–90% less per month, compounded alternatives are financially accessible to a much larger population.
However, price isn't the only consideration. FDA-approved medications undergo rigorous clinical testing for the specific formulation — meaning the oral Wegovy tablet has been tested as a complete product (active ingredient plus delivery technology) in large clinical trials. Compounded oral formulations use the same active ingredient but in pharmacy-developed delivery formats that haven't undergone the same formulation-specific clinical trials.
For patients with insurance coverage that includes oral Wegovy, the brand-name option may cost little more than a copay. For cash-pay patients without coverage, the math strongly favors compounded alternatives.
The Absorption Factor
Oral semaglutide has inherently lower bioavailability than injectable semaglutide — meaning a smaller percentage of the active ingredient reaches your bloodstream. This is true for both brand-name and compounded oral formulations, though the specific bioavailability varies by delivery format.
Brand-name oral Wegovy uses a proprietary absorption enhancer (SNAC technology) to improve bioavailability. Compounded sublingual formulations take a different approach, using the highly vascular tissue under the tongue for more direct absorption into the bloodstream.
In practice, providers adjust dosing to account for bioavailability differences, so patients on oral formulations may take higher nominal doses to achieve equivalent blood levels to injectable patients.
Who Should Consider Each Option
Oral Wegovy may be right if:
You have insurance coverage that includes it, reducing your out-of-pocket cost. You strongly prefer FDA-approved medications. You value the clinical trial data specific to the exact formulation you're taking. Your prescribing physician recommends brand-name formulations.
Compounded oral semaglutide may be right if:
You're paying cash and need affordable access to GLP-1 treatment. You want to avoid injections but can't afford brand-name oral pricing. You're comfortable with compounded medications prepared by licensed pharmacies. Your telehealth provider offers a well-structured oral program with proper medical oversight.
For patients choosing the brand-name route, Sesame Care provides access to FDA-approved oral and injectable GLP-1 medications.
View Sesame Care →Providers Offering Oral GLP-1 Options
Not all telehealth providers offer oral GLP-1 formats. Here are providers with strong GLP-1 programs that may include oral options — check directly with each provider for their current oral availability:
The Bottom Line
The oral GLP-1 market has expanded meaningfully since oral Wegovy's approval. Patients now have genuine choice between brand-name and compounded oral options — a choice that didn't exist just a year ago.
For most cash-pay patients, compounded oral semaglutide offers the best combination of affordability, convenience, and access. For insured patients with coverage, brand-name oral Wegovy provides the reassurance of FDA-approved formulation-specific clinical data.
Either way, the fact that effective oral GLP-1 options exist at all is great news for the millions of patients who want the benefits of GLP-1 treatment without injections.
Looking for injectable options instead? Check our complete Price Index for comprehensive pricing across all GLP-1 formats and providers.